Allegro DVT Fosters Adoption of MPEG-5 LCEVC Video Codec, Releases a Full Range of LCEVC Products
Allegro DVT, a leading provider of Video codec compliance streams and silicon video IP solutions has launched a complete range of MPEG-5 LCEVC products comprising LCEVC compliance streams and LCEVC hardware decoder and encoder video IPs (D301 and E301).
Allegro DVT’s LCEVC Compliance Streams are crucial to confirm that decoder implementations adhere to the LCEVC standard. They are used by all companies developing SoCs or devices with LCEVC decoding capabilities.
Furthermore, Allegro DVT is also releasing its E301 LCEVC Encoding HW IP which complements its D301 LCEVC Decoding HW IP that was previously announced at NAB in April 2023. This full range of LCEVC HW IPs is suitable for integration into SoCs/ASICs requiring HW based support for LCEVC encoding and decoding functions.
The E301 is the industry’s first LCEVC encoding IP solution and was developed in close collaboration with V-Nova, the inventor of the LCEVC technology. It is optimized for power and silicon area, allows system-on-chip (SoC) and ASIC designers to easily integrate LCEVC encoding into their products. It supports picture resolution up to 8K, pixel widths from 8 to 12-bits and chroma subsampling formats ranging from 4:2:0 up to 4:4:4. The IP also features fast and easy SoC integration and is delivered with full user configurable control software.
Guido Meardi, CEO of V-Nova commented “As LCEVC continues its progression in the industry, a holistic suite of hardware IP tools including decoding, encoding, and verification platforms had become essential. Allegro DVT's offerings are perfectly timed to meet this emerging trend, reinforcing the momentum behind LCEVC. Their products will not only fuel LCEVC's adoption but also cement its position as a transformative force that many are already integrating into their plans.”
Nouar Hamze, CEO of Allegro DVT added “With today’s announcement, Allegro DVT has truly become a one-stop-shop for SoC/ASIC designers who need to rapidly add LCEVC encoding/decoding function into their products. Our E301 LCEVC Encoding IP, developed and benchmarked in collaboration with V-Nova, produces the best encoding video quality that fully unlocks the potential of the LCEVC technology. Together with our D301 LCEVC Decoding IP and LCEVC compliance streams, we are enabling an easy and seamless path for SoCs/ASIC companies to integrate and verify the new LCEVC standard into their products, giving them a tremendous competitive advantage.”
MPEG-5 part 2 LCEVC (Low Complexity Enhancement Video Coding) is the latest standard by MPEG and ISO. Instead of replacing existing codecs, LCEVC enhances them, reducing both costs and energy consumption of the transcoding process by up to 70%. Remarkably, it also augments compression efficiency by up to 40%, with benefits that stack upon those of other methods to improve video compression, rather than being an alternative. It specifies an enhancement layer which, when combined with a base video encoded with a separate codec, produces an enhanced video stream. LCEVC also enables unique benefits in applications such as single-stream SDR-HDR backward-compatible delivery and low-latency video delivery.
To find out more about Allegro DVT’s LCEVC products, come and visit Allegro DVT booth 5.A25 at IBC Amsterdam 15-18 September 2023.
About Allegro DVT
Allegro DVT is a world leading provider of digital video technology solutions including compliance streams and video codec semiconductor IPs focused on H.264, HEVC, VP9, AV1, VVC and LCEVC standards.
About V-Nova
V-Nova is committed to unlocking higher quality digital experiences at scale. Its technologies, based on the innovative use of AI and parallel processing improve data, video, imaging, point-cloud compression and have been granted international standard status by MPEG, ISO and SMPTE. V-Nova’s relentless investment in R&D has built a portfolio of over 700 international patents, along with a range of software products and solutions.
For more about V-Nova, please visit: www.v-nova.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831702100/en/
Contact information
Allegro DVT press:
Stéphanie Nastasi – Communication Manager
marcom@allegrodvt.com
V-Nova press:
Jose D. Guariglia – PR Account Manager, Bubble UK and EMEA
jd@bubbleagency.com
Casey Love – PR Account Manager, Bubble USA
caseyl@bubbleagency.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom